Literature DB >> 16103889

A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression.

S Horschitz1, R Hummerich, T Lau, M Rietschel, P Schloss.   

Abstract

The dopamine transporter (DAT) plays a crucial role in dopaminergic neurotransmission as it clears the extracellular space of dopamine (DA) and thus controls the concentration of active neurotransmitter. Genetic association studies have reported a variable number of tandem repeat polymorphisms in the 3'-noncoding region of the DAT gene implicating this protein in the development of various psychiatric disorders. In a sample of bipolar patients, two rare missense substitutions (A559V and E602G) have been identified, one of which (E602G) was inherited by the patient from her affected father. None of these mutations had been identified in any control subjects of this survey. Using a heterologous cellular expression system, we have analysed possible consequences of these mutations on functional properties of the encoded DAT protein. DA transport measurements and antagonist binding revealed that the A559V mutant protein is fully functional, whereas the E602G mutant is not. Further analyses by confocal microscopy showed that the E602G protein is transcribed and translated but not delivered to the cell surface. Taken together, our results suggest that this missense mutation has functional consequences thus supporting the need to screen larger samples of patients and their relatives for this rare but bipolar disorder-associated mutation in the DAT gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103889     DOI: 10.1038/sj.mp.4001730

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  35 in total

1.  Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony.

Authors:  Kafui Dzirasa; H Westley Phillips; Tatyana D Sotnikova; Ali Salahpour; Sunil Kumar; Raul R Gainetdinov; Marc G Caron; Miguel A L Nicolelis
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats.

Authors:  Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 3.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

Review 4.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 5.  Investigating the mechanism(s) underlying switching between states in bipolar disorder.

Authors:  Jared W Young; Davide Dulcis
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

6.  The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania.

Authors:  Morgane Milienne-Petiot; James P Kesby; Mary Graves; Jordy van Enkhuizen; Svetlana Semenova; Arpi Minassian; Athina Markou; Mark A Geyer; Jared W Young
Journal:  Neuropharmacology       Date:  2016-10-11       Impact factor: 5.250

7.  Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Klaas Kooistra; Jared W Young
Journal:  Int J Neuropsychopharmacol       Date:  2012-11-20       Impact factor: 5.176

8.  Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Adam L Halberstadt; Xiaoxi Zhuang; Jared W Young
Journal:  J Affect Disord       Date:  2013-11-16       Impact factor: 4.839

9.  GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior.

Authors:  Jared W Young; Andrew K L Goey; Arpi Minassian; William Perry; Martin P Paulus; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-12-18       Impact factor: 4.530

10.  Persistent hyperdopaminergia decreases the peak frequency of hippocampal theta oscillations during quiet waking and REM sleep.

Authors:  Kafui Dzirasa; Lucas M Santos; Sidarta Ribeiro; Jennifer Stapleton; Raul R Gainetdinov; Marc G Caron; Miguel A L Nicolelis
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.